Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha. The company also develops ONS-1045, a bevacizumab biosimilar, which is in a Phase 1 clinical trial that interferes with tumor growth by binding to vascular endothelial growth factor, a protein that stimulates the formation of new blood vessels. Its advanced preclinical product candidate is ONS-1050, a trastuzumab biosimilar, interferes with the human epidermal growth factor receptor 2, a protein that stimulates cell proliferation. Oncobiologics, Inc. has collaboration and license agreements with Selexis SA; IPCA Laboratories Limited; Laboratories Liomont, S.A. de C.V.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONS
Previous SymbolNYSE:ONS
CUSIPN/A
Phone609-619-3990
Debt
Debt-to-Equity RatioN/A
Current Ratio0.41
Quick Ratio0.41
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.81 million
Price / Sales8.34
Cash FlowN/A
Price / Cash FlowN/A
Book Value($1.36) per share
Price / Book-0.32
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-38,840,000.00
Net Margins-464.47%
Return on EquityN/A
Return on Assets-93.28%
Miscellaneous
Employees48
Outstanding Shares72,200,000
Market Cap$46.35 million
OptionableNot Optionable
Oncobiologics (NASDAQ:ONS) Frequently Asked Questions
What is Oncobiologics' stock symbol?
Oncobiologics trades on the NASDAQ under the ticker symbol "ONS."
What is the consensus analysts' recommendation for Oncobiologics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncobiologics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Oncobiologics.
Has Oncobiologics been receiving favorable news coverage?
News articles about ONS stock have been trending somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oncobiologics earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Oncobiologics' key competitors?
Some companies that are related to Oncobiologics include Neon Therapeutics (NTGN), Allena Pharmaceuticals (ALNA), Compugen (CGEN), Erytech Pharma (ERYP), Fennec Pharmaceuticals (FENC), Organovo (ONVO), Jounce Therapeutics (JNCE), Champions Oncology (CSBR), Idera Pharmaceuticals (IDRA), Nantkwest (NK), Pluristem Therapeutics (PSTI), Aptose Biosciences (APTO), Aevi Genomic Medicine (GNMX), Cidara Therapeutics (CDTX) and BioCardia (BCDA).
Who are Oncobiologics' key executives?
Oncobiologics' management team includes the folowing people:
- Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Principal Accounting Officer, Company Sec.,Treasurer & Director (Age 52)
- Dr. Pankaj Mohan, Founder & Director (Age 53)
- Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 65)
- Mr. Ralph H. Thurman, Exec. Chairman (Age 69)
- Rick Gregory, Director of Marketing & Communications
When did Oncobiologics IPO?
(ONS) raised $35 million in an IPO on Friday, May 13th 2016. The company issued 5,800,000 shares at a price of $6.00 per share. Jefferies and Barclays acted as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.
Who are Oncobiologics' major shareholders?
Oncobiologics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc (0.79%) and Vanguard Group Inc. (0.79%). Company insiders that own Oncobiologics stock include Elizabeth A Yamashita, Kenneth Bahrt, Lawrence A Kenyon, Pankaj Mohan and Stephen J Mcandrew. View Institutional Ownership Trends for Oncobiologics.
Which institutional investors are buying Oncobiologics stock?
How do I buy shares of Oncobiologics?
Shares of ONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oncobiologics' stock price today?
One share of ONS stock can currently be purchased for approximately $0.44.
How big of a company is Oncobiologics?
Oncobiologics has a market capitalization of $46.35 million and generates $3.81 million in revenue each year. Oncobiologics employs 48 workers across the globe.
What is Oncobiologics' official website?
How can I contact Oncobiologics?
Oncobiologics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]
MarketBeat Community Rating for Oncobiologics (NASDAQ ONS)
MarketBeat's community ratings are surveys of what our community members think about Oncobiologics and other stocks. Vote "Outperform" if you believe ONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
